Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue grows, but more slowly than its trailing trend

Q1 FY2026 revenue of $51.72M rose 3.4% year over year, behind the +8.2% change in trailing-twelve-month revenue. Sequentially, it fell 9.6% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $242.13M (+12.0%) for the fiscal year ending Dec 2026, a step up from the +8.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.72M-9.6% QoQ
Last fiscal yearDec 2025
$216.11M+8.7% YoY
LTMMar 2026
$217.78M+8.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%+17.8%+14.4 pp
1 year+8.7%+12.0%+3.3 pp
3-year CAGR-5.3%+18.4%+23.7 pp
5-year CAGR+17.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
216.11M USD
Year-over-year change
+8.7%
4-year CAGR
-5.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 revenue of $217.78M is the highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +8.2% is the highest of 6, against a peer median of -74.0%.
  • Over three fiscal years its annual growth of -5.3% compares with a peer median of -0.4%.
VNDA Competitors Peer median
Revenue for VNDA and competitors
Company Period LTM YoY 3-year CAGR
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$217.78M +8.2%-5.3%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$45.35M -66.4%-31.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$36.49M -45.5%-0.4%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$5.74M -96.7%—
HUMAHumacyte, Inc.LTM Mar 2026$2.02M -74.0%+9.2%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 ——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 -100.0%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 ——
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 ——
IMRXImmuneering CorporationLTM Mar 2026$0 ——
Peer median (excluding VNDA) $0-74.0%-0.4%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.